Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma drug market, driven by the launch of emerging agents, will experience robust annual 12 percent growth through 2012 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Thereafter, the market will grow by six percent annually through 2017.

The new Pharmacor report entitled Malignant Melanoma finds that the launch of Bristol-Myers Squibb/Medarex's ipilimumab, first in the metastatic setting and later in the adjuvant setting, will significantly increase the size of the malignant melanoma drug market as sales of ipilimumab will grow at an annual rate of 17 percent from 2012 through 2017. In addition to ipilimumab, other emerging therapies that will drive growth include GlaxoSmithKline/Synta's elesclomol, Abraxis's Abraxane, Schering-Plough's PEG Intron/Roche's Pegasys and Genta's Genasense. Ipilimumab will command the largest total market share, accounting for nearly a quarter of malignant melanoma drug sales in 2012 and just over a third of sales in 2017.

The report also finds that, as a result of recently published data on vaccines in malignant melanoma, interviewed experts lack confidence in the vaccine drug class. Among cancer vaccines that had been previously regarded as promising emerging agents, Progenics' GM2-KLH21 has recently shown to be detrimental in early stage malignant melanoma.

"The incidence of malignant melanoma is rising rapidly, resulting in an increasing drug-treated population," said Marcus Hoyle, analyst at Decision Resources. "A huge unmet need in the treatment of this cancer remains for the development of therapies that can prolong overall survival in the advanced stages as prognosis at this stage is poor with a median overall survival of six to nine months."

About Decision Resources

Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com/.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources              Decision Resources, Inc.   Christopher Comfort             Elizabeth Marshall   781-296-2597                    781-296-2563   ccomfort@dresources.com         emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

Contact: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

End of Private Fee-for-Service Medicare Plans Creates Significant Competition in TriState Area

View Now